Claret Capital Partners raises €575 million Fund IV to boost European biotech lending
read at Endpoints ↗DealNeutral
Claret Capital Partners, a European investment firm, announced that its fourth fund has closed at €575 million.
The firm said a significant share of the capital will be deployed as loans to life-science companies and manufacturers operating in Europe, reflecting a shift toward supporting regional biotech development.
By focusing on debt financing rather than equity, Claret aims to provide flexible funding to help European biotech firms scale their operations while preserving ownership structures.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Claret says its latest fund will have larger focus on European life sciences”
read at Endpoints ↗84 words · retrieved Sep 7
comments(0)
5-min edit window · permanent after that